Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Childhood acute lymphoblastic leukemia
Relapsed and refractory disease after frontline cure rates: blinatumomab, inotuzumab and CD19 CAR-T cells.
ESMO Congress 2026
23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement
The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.
Indexed in Crossref
The ESMO Congress 2026 supplement (Annals of Oncology, vol. 37 supplement) was not in Crossref when last checked on 11 Nov 2026. No verified pull has been made for this indication yet.